MRNA shot takes on MS: moderna launches brain lesion trial

NCT ID NCT06735248

Recruiting now Disease control Sponsor: ModernaTX, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 39 times

Summary

This Phase 2 trial tests an experimental mRNA therapy called mRNA-1195 in 180 adults aged 18 to 55 with relapsing multiple sclerosis. Participants receive either the mRNA shot or a placebo, and researchers monitor safety and measure new brain lesions on MRI scans over about 2.5 years. The goal is to see if the treatment is safe and may reduce disease activity.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

ANESC Research
RECRUITING

El Paso, Texas, 79912, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
Anne Rowling Regenerative Neurology Clinic, University of Edinburgh
RECRUITING

Edinburgh, EH16 4SB, United Kingdom
Boston Clinical Trials Inc - Internal Medicine
TERMINATED

Boston, Massachusetts, 02131, United States
Cambridge Clinical Research Centre
RECRUITING

London, CB2 0SL, United Kingdom
Cardiff and Vale University Health Board - University Hospital Wales
RECRUITING

Cardiff, CF14 4XW, United Kingdom
East Kent Hospitals University NHS Foundation Trust
RECRUITING

London, CT1 3NG, United Kingdom
NHS Greater Glasgow & Clyde - Institute of Neurological Sciences
RECRUITING

Glasgow, G51 4TF, United Kingdom
North Bristol NHS Trust - Southmead Hospital
RECRUITING

Bristol, BS10 5NB, United Kingdom
Oklahoma Medical Research Foundation (OMRF) MS Center of Excellence
RECRUITING

Oklahoma City, Oklahoma, 73104, United States
Quest Research Institute
RECRUITING

Farmington Hills, Michigan, 48334, United States
Saturn Research Solutions
RECRUITING

Plano, Texas, 75024, United States
Sharlin Health & Neurology
TERMINATED

Ozark, Missouri, 65721, United States
Sheffield Teaching Hospital NHS foundation Trust, Herries Road
RECRUITING

Sheffield, S10 2JF, United Kingdom
The Newcastle Upon Tyne Hospitals NHS Foundation Trust
RECRUITING

Newcastle upon Tyne, NE14LP, United Kingdom
University of Texas Southwestern Medical Center
RECRUITING

Dallas, Texas, 75390-8806, United States
University of the Sunshine Coast Clinical Trials
RECRUITING

Birtinya, Queensland, 04575, Australia
Washington University School of Medicine Neurology Clinical Unit
RECRUITING

St Louis, Missouri, 63110, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

mRNA-1195 (a messenger RNA therapy given as a shot into the muscle)

What this could lead to

If successful, this could point toward a new treatment option that reduces brain lesions and slows disease activity in relapsing multiple sclerosis.

What could go wrong

This is an early Phase 2 trial with only 180 participants, so results may not apply to everyone. The main goal is safety, not yet proof of effectiveness. Side effects from the injection or immune reactions are possible.

Conditions

The condition(s) this trial relates to.

multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS